Trial · NCT04619862
Efficacy of Gabapentin in Treating Pain in Children With SNI (Gabapentin Trial)
NCT04619862, Phase 2, Unknown, University of British Columbia
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Efficacy of Gabapentin in Treating Pain in Children With SNI (Gabapentin Trial). Trials, record NCT04619862. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04619862
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy of Gabapentin in Treating Pain in Children With SNI (Gabapentin Trial)
- NCT number
- NCT04619862
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 5 participants, estimated
- Lead sponsor
- University of British Columbia
- Conditions
- Pain, Neuropathic Pain, Irritability
- Interventions
- Gabapentin, Placebo
- First posted
- 2020-11-06
- Last updated
- 2024-05-08
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mean pain and irritability score | Days 11-19 | The mean pain and irritability score on the Non-Communicating Children's Pain Checklist Revised (NCCPC-R) on active drug compared to placebo. |
| Secondary | Identification of lowest effective dose | Days 11-19 on active drug | For patients who benefited from gabapentin, identification of the lowest dose that was effective in reducing pain scores, as shown by a lower Non-Communication Children's Pain Checklist - Revised (NCCPC-R) score compared to baseline. |
| Secondary | Maximal effect dosage | Days 11-19 on active drug | For patients who benefited from gabapentin, identification of the maximal effect dosage as measured by the largest improvement in the Non-Communicating Children's Pain Checklist - Revised (NCCPC-R) score compared to baseline. |
| Secondary | Identification of latency time | Days 0-19 | Identification of the latency time in days to the onset of maximum relief of pain and irritability as measured by the Non-Communication Children's Pain Checklist - Revised (NCCPC-R) score |
| Secondary | Adverse Events collection | Through Sequence 1 and 2, total of 55 days | Adverse Events collection demonstrates the AEs on treatment arm do not exceed the frequency found in the Product Monograph for children receiving gabapentin |
| Other | Improvement in parent fatigue levels | Day 1 of Sequence 1 and 2 (each Sequence is 26 days with a 3 day washout period in between) and Study End, day 55 | Patient Reported Outcome Measures Information System - 57 (PROMIS-57) scores on the medication arm compared to the placebo arm |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04619862
GET https://conductscience.org/api/trials/v1/NCT04619862/registered